SAFETY AND PRELIMINARY EFFICACY OF THE FARNESOID X RECEPTOR (FXR) AGONIST CILOFEXOR IN A 96-WEEK OPEN-LABEL EXTENSION OF A PHASE 2 STUDY OF PSCMichael H. Trauner,Aliya F. Gulamhusein,Bilal Hameed,Stephen Caldwell,Mitchell L. Shiffman,Charles Landis,Andrew Joseph Muir,Jun Xu,Xiaomin Lu,Chuhan Chung,Robert P. Myers,Christopher L. Bowlus,Kris V. KowdleyHEPATOLOGY(2021)引用 0|浏览4暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要